Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of SGLT2 Inhibitors on AF Recurrence After Catheter Ablation in Patients With Type 2 Diabetes
Moh’d Rasheed Abu-Qaoud, Ashish Kumar, Tushar Tarun, et al.
JACC. Clinical electrophysiology (2023) Vol. 9, Iss. 10, pp. 2109-2118
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

SGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials
Marco Valerio Mariani, Giovanna Manzi, Nicola Pierucci, et al.
Journal of Cardiovascular Electrophysiology (2024) Vol. 35, Iss. 9, pp. 1754-1765
Closed Access | Times Cited: 23
GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors
Rushin Patel, Mark Wadid, Bhargav Makwana, et al.
JACC Heart Failure (2024) Vol. 12, Iss. 11, pp. 1814-1826
Closed Access | Times Cited: 9
The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review
Panagiotis Stachteas, Athina Nasoufidou, Efstratios Karagiannidis, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5408-5408
Open Access | Times Cited: 8
Impact of sodium-glucose cotransporter 2 inhibitors on catheter ablation for atrial fibrillation in heart failure patients without type-2 diabetes
Masafumi Harada, Yuji Motoike, Y. Nomura, et al.
International Journal of Cardiology (2025) Vol. 422, pp. 132954-132954
Open Access | Times Cited: 1
Impact of Sodium‐Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With Diabetes: A Propensity‐Score Matching Study and Meta‐Analysis
Zixu Zhao, Chao Jiang, Liu He, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 24
Open Access | Times Cited: 17
Emerging role of antidiabetic drugs in cardiorenal protection
Wen-Jia Fu, Jin-Ling Huo, Zi‐Hui Mao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
Efficacy of sodium-glucose cotransporter 2 inhibitors in preventing AF recurrence after catheter ablation
Panagiotis Stachteas, Paschalis Karakasis, Efstratios Karagiannidis, et al.
Hellenic Journal of Cardiology (2024) Vol. 79, pp. 86-87
Open Access | Times Cited: 7
Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond
Massimiliano Camilli, Marcello Viscovo, Luca Maggio, et al.
Basic Research in Cardiology (2024)
Open Access | Times Cited: 7
Glucagon-Like Peptide-1 Receptor Agonists and Atrial Fibrillation Recurrence After Ablation
Paschalis Karakasis, Dimitrios Patoulias, Stylianos Tzeis, et al.
JACC. Clinical electrophysiology (2024) Vol. 10, Iss. 8, pp. 1940-1941
Closed Access | Times Cited: 7
Efficacy of dapagliflozin in improving arrhythmia-related outcomes after ablation for atrial fibrillation: a retrospective single-center study
H. Noh, Sung Joo, Chee Hae Kim, et al.
Clinical Research in Cardiology (2024) Vol. 113, Iss. 6, pp. 924-932
Closed Access | Times Cited: 6
SGLT2 inhibitors and the cardiac rhythm: unraveling the connections
Aritra Paul, Chadi Tabaja, Oussama M. Wazni
International Journal of Arrhythmia (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 5
The potential anti-arrhythmic effect of SGLT2 inhibitors
Hong-Yi Duan, Héctor Barajas-Martínez, Charles Antzelevitch, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Mitral regurgitation in heart failure with preserved ejection fraction: The interplay of valve, ventricle, and atrium
Sebastiaan Dhont, Gitte van den Acker, Tim van Loon, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 4, pp. 974-983
Closed Access | Times Cited: 4
Integrated Management of Persistent Atrial Fibrillation
Xindi Yue, Ling Zhou, Chunxia Zhao
Biomedicines (2025) Vol. 13, Iss. 1, pp. 91-91
Open Access
Impact of Sodium‐Glucose Co‐Transporter 2 Inhibitors on Atrial Fibrillation Recurrence Post‐Catheter Ablation Among Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
Naser Abdelhadi, Khaled Mohamed Ragab, Mohammed Elkholy, et al.
Journal of Cardiovascular Electrophysiology (2025)
Open Access
Effect of Sodium-Glucose Cotransporter Type 2 Inhibitors on The Development and Course of Atrial Fibrillation
D. A. Ishmaev, Magdalena Vasileva, D. V. Duplyakov
The Russian Archives of Internal Medicine (2025) Vol. 15, Iss. 1, pp. 17-23
Open Access
Metabolic dysfunction associated steatotic liver disease is associated with atrial fibrillation recurrence following cryoballoon ablation
Yu Wang, Zheng Chen, Bo Wei, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
The Impact of SGLT2 Inhibitors on Atrial Fibrillation Recurrence and Long‐Term Clinical Outcomes in HFrEF Patients Undergoing Cryoballoon Ablation: A New Frontier Beyond Diabetes and Heart Failure
Elif Hande Özcan Çetin, Mehmet Serkan Çetin, Hasan Can Könte, et al.
Journal of Cardiovascular Electrophysiology (2025)
Closed Access
SGLT2 inhibitors and nephrolithiasis risk in patients with type 2 diabetes: A cohort study and meta-analysis
Jia-Ai Yeh, Yu‐Chang Liu, Amy Huang, et al.
Diabetes Research and Clinical Practice (2025), pp. 112088-112088
Closed Access
Atrial Fibrillation (AF) and Heart Failure With Preserved Ejection Fraction (HFpEF): Advances and Challenges
Sanjeev Saksena, April Slee, Ranghadham Nagarakanti, et al.
Journal of Cardiovascular Electrophysiology (2025)
Open Access
Efficacy of sodium-glucose cotransporter 2 inhibitors on preventing atrial arrhythmia recurrences after atrial fibrillation ablation in patients with heart failure
Takashi Okajima, Shinji Ishikawa, Yusuke Uemura, et al.
Journal of Cardiology (2025)
Closed Access
SGLT2 inhibitors in atrial fibrillation: Ready for prime time?
Arturo Cesaro, Vincenzo Acerbo, Felice Gragnano, et al.
International Journal of Cardiology (2025), pp. 133186-133186
Closed Access
The Influence of Risk Factor Modification on Atrial Fibrillation Outcomes and Their Impact on the Success of Catheter Ablation
Nakul Chandan, Vishnu Ashok, T. S. HWANG, et al.
Reviews in Cardiovascular Medicine (2025) Vol. 26, Iss. 3
Open Access
Diabetes and Atrial Fibrillation: Insight From Basic to Translational Science Into the Mechanisms and Management
Bharat K. Kantharia, Mohammadreza Tabary, Lingling Wu, et al.
Journal of Cardiovascular Electrophysiology (2025)
Closed Access
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Atrial Fibrillation Recurrence After Catheter Ablation
Danish Iltaf Satti, Alexander K. Karius, Jeffrey Shi Kai Chan, et al.
JACC. Clinical electrophysiology (2024) Vol. 10, Iss. 8, pp. 1848-1855
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top